Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial-Reference-Cited by-同舟云学术

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Published:2019-01 Issue:1 Volume:20 Page:110-119
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lombardi Giuseppe,De Salvo Gian Luca,Brandes Alba Ariela,Eoli Marica,Rudà Roberta,Faedi Marina,Lolli Ivan,Pace Andrea,Daniele Bruno,Pasqualetti Francesco,Rizzato Simona,Bellu Luisa,Pambuku Ardi,Farina Miriam,Magni Giovanna,Indraccolo Stefano,Gardiman Marina Paola,Soffietti Riccardo,Zagonel Vittorina

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone;Kruchko;Neuro Oncol,2018

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

3. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme;Ronning;Neuro Oncol,2012

4. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas;Weller;Lancet Oncol,2017

5. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma;Batchelor;J Clin Oncol,2010

Cited by 266 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials;Cancers;2024-08-29

2. Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol;PLOS ONE;2024-07-26

3. Neuroinflammation in Glioblastoma: Progress and Perspectives;Brain Sciences;2024-07-09

4. Targeting drug resistance in glioblastoma (Review);International Journal of Oncology;2024-07-09

5. Current status of precision oncology in adult glioblastoma;Molecular Oncology;2024-06-20